Search the Newsreel

Acadia Realty Trust (NYSE:AKR) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded Acadia Realty Trust (NYSE:AKR) from "sell" to "hold." Despite this, the company reported Q2 EPS of $0.05, missing analyst estimates, though revenue of $95.42 million exceeded expectations. Analysts maintain a "Moderate Buy" consensus with an average price target of $24.00 …

Acadian Asset Management (NYSE:AAMI) Combines Strong Growth with a Top-Tier Technical Setup

ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside

The average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) stock has been lowered from $33.65 to $33.05 by 19 analysts, with a range of $17 to $41 per share. This new target suggests a potential 17% upside based on the August 14 closing …

Acadian Asset Management (NYSE:AAMI) Sets New 52-Week High - Should You Buy?

Should You Continue to Hold ACHC Stock at an 18.17X P/E Valuation?

Acadia Healthcare Company, Inc.ACHC benefits from strong long-term demand for behavioral health services. The company is expanding its network through joint ventures, de novo facilities and bed additions. Shares of ACHC have surged 113.1% year to date, significantly outperforming the industry's 13.2% growth during …

UBS Adjusts Price Target on Acadia Healthcare to $1.50 From $4.50, Keeps Neutral Rating

UBS has adjusted its price target for Acadia Healthcare (referred to as Accendra Health in the article) to $1.50, down from $4.50, while maintaining a Neutral rating on the stock. This adjustment follows similar downgrades and price target reductions from other firms like Citigroup …

Cohen & Steers (AKR) reports 20.1M Acadia Realty Trust shares in 13G/A filing

Cohen & Steers has filed an amended Schedule 13G, disclosing its passive ownership of 20,149,944 shares, or 14.13%, of Acadia Realty Trust's common stock. The filing indicates that Cohen & Steers entities possess sole voting power over 15,530,098 shares, with no shared voting or …

STATE STREET CORP Expands Acadia Realty Trust (AKR) Stake -- Shares Trade 11% Above GF Value

Wellington Group (ACHC) discloses 6.15% beneficial stake in Acadia Healthcare

Wellington Management Group LLP and its related entities have disclosed a 6.15% beneficial ownership stake in Acadia Healthcare Company, Inc. (ACHC) through a Schedule 13G/A SEC filing. The ownership is held by investment advisory clients of various Wellington investment advisers, indicating shared voting and …

ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts

Argus has raised its target price for ACADIA Pharmaceuticals Inc. (ACAD) to $31.00, up from its previous rating. The biopharmaceutical company focuses on developing and commercializing medicines for central nervous system (CNS) disorders and rare diseases. This report, published on August 12, 2026, highlights …

Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD

Royal Bank of Canada reduced its stake in ACADIA Pharmaceuticals Inc. by 23.3% in the first quarter, selling 67,699 shares but still holding 223,155 shares valued at $4.97 million. This comes as institutional investors own 96.71% of the company. ACADIA Pharmaceuticals reported strong quarterly …

Truist Financial Maintains Acadia Realty Trust(AKR.US) With Buy Rating

Truist Financial has reiterated its Buy rating on Acadia Realty Trust (AKR.US). This continued endorsement from Truist Financial suggests a positive outlook for the real estate investment trust.

ACADIA Pharmaceuticals (ACAD) On Raised 2026 Guidance And Strong Results Looks Undervalued

ACADIA Pharmaceuticals (ACAD) has seen its stock gain attention after raising its 2026 revenue guidance to between US$1.24 billion and US$1.30 billion, driven by strong second-quarter results. The company's pipeline, with nine disclosed programs, suggests diversification beyond its current key products, contributing to a …

How Investors Are Reacting To Academy Sports (ASO) Expanding Same-Day Delivery And Retail Media Ambitions

Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com

Acadia Pharmaceuticals (ACAD) stock reached a new 52-week high of $29.81, trading at $29.77, marking a 36% surge over the last six months. This growth is supported by strong Q2 2026 revenues of $308 million, exceeding estimates, driven by robust sales of Daybue. Analysts …

Did Acadia Healthcare Company, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Acadia Healthcare Company, Inc. (NASDAQ: ACHC) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of Acadia stock to contact them to discuss potential legal rights and …

ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC

Needham & Company LLC has raised its price target for ACADIA Pharmaceuticals (NASDAQ:ACAD) from $38.00 to $41.00, maintaining a "Buy" rating, which suggests a potential upside of 39.41%. This comes as the biopharmaceutical company exceeded quarterly earnings expectations, reporting $0.18 EPS against an anticipated …

Royal Bank of Canada Purchases 274,785 Shares of Acadia Healthcare Company, Inc. $ACHC

Royal Bank of Canada significantly increased its stake in Acadia Healthcare Company, Inc. (ACHC) by 7,896.1% in the first quarter, acquiring an additional 274,785 shares. The fund now holds 278,265 shares valued at approximately $6.5 million. This increase makes Royal Bank of Canada a …

Accendra Health (ACHC) Stock Sinks As Losses Deepen And Cash Stays Tight

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026, at 4:30 p.m. ET CALL PARTICIPANTS Senior Vice President, Investor Relations and Corporate Development - Albert KildaniChief Executive Officer - Catherine Owen AdamsChief Commercial Officer - Thomas GarnerExecutive Vice President, Head of Research and …

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Acadia Healthcare

Faruqi & Faruqi, LLP is investigating potential securities claims against Acadia Healthcare Company, Inc. on behalf of investors who suffered losses exceeding $100,000 between February 28, 2020, and September 26, 2024. The investigation stems from allegations that Acadia Healthcare made false and misleading statements …

Acadia Realty Trust (AKR) Affirmed Its Dividend And Updated Guidance, Is It Still Below Fair Value?

Acadia Realty Trust (AKR) recently affirmed its quarterly dividend of $0.20 per share and updated its 2026 earnings guidance. Despite a short-term share price dip, the company has shown strong longer-term returns and is considered 17.1% undervalued with a fair value of $24.43. However, …

Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating

Morgan Stanley has increased its price target for ACADIA Pharmaceuticals (ACAD) from $26 to $27, while maintaining an Equalweight rating on the stock. This adjustment reflects a modest positive outlook on the company's valuation by the firm.

Academy Sports and Outdoors (ASO) Short Interest & Short Float | Updated Aug 2026

This article provides an updated overview of Academy Sports and Outdoors (ASO) short interest data as of July 31, 2026. It details that ASO's short interest increased by 0.80% to 7.81 million shares, representing 13.13% of the public float, with a short interest ratio …

Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD

Janus Henderson Group PLC significantly reduced its stake in ACADIA Pharmaceuticals Inc. by 82.3% in the first quarter, selling over 238,000 shares. Despite this, other major institutional investors increased their positions, and collective institutional ownership remains high at 96.71%. ACADIA Pharmaceuticals reported strong quarterly …

Quantinno Capital Management LP Buys 87,870 Shares of Acadia Realty Trust $AKR

Quantinno Capital Management LP significantly increased its stake in Acadia Realty Trust (NYSE:AKR) by 293.3% in the first quarter, now owning 117,831 shares valued at $2.25 million. Despite missing EPS estimates, Acadia Realty Trust's revenue exceeded expectations, and the company announced a quarterly dividend …

The Bull Case For Acadian Asset Management (AAMI) Could Change Following Strong Q2 Results And Capital Returns - Learn Why

Academy Sports partners with Instacart for same-day delivery in as fast as one hour

Academy Sports & Outdoors has partnered with Instacart to provide same-day delivery services, with orders fulfilled in as fast as one hour. This collaboration expands Academy's omnichannel reach to over 300 stores across 21 states, allowing customers to access their full product assortment through …

ACADIA Pharmaceuticals Inc. Revenue Breakdown – BIVA:ACAD

ACADIA Pharmaceuticals Inc. (BIVA:ACAD) generated 19.32 billion MXN in revenue last year, primarily from its Innovative Medicines segment. The company's revenue decreased slightly from 19.97 billion MXN the previous year. The United States was the largest contributor to revenue, accounting for the entire 19.32 …

Acadia Realty Trust (AKR) Dividend Affirmation Keeps Fair Value In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Dividend affirmation puts focus on Acadia Realty Trust Acadia Realty Trust (AKR) recently affirmed a quarterly cash dividend of $0.20 per common share, …

Acadia Realty Trust (AKR) Stock Could Be Trading Below Fair Value

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Acadia Realty Trust stock has delivered a 50.5% return over the past three years, …

Acadia Healthcare Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Acadia Healthcare Company, Inc. - ACHC

Kahn Swick & Foti, LLC (KSF) is continuing its investigation into Acadia Healthcare Company, Inc. (ACHC) regarding potential breaches of fiduciary duties by its officers and directors and violations of state or federal laws. This investigation follows disclosures by Acadia Healthcare concerning a federal …

Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says

Acadia Pharmaceuticals (ACAD) could benefit from wider Daybue use, steady Nuplazid growth, higher cash flow and a strong balance sheet, but upcoming Remlifanserin trial data and the stock's valuation keep the outlook balanced, Morgan Stanley said in a note emailed Monday.STIX Silver Upgrade to …